Pfizer Increasing Size of China R&D Center, Expanding Virtual Research Network Through Alliances With Chinese Scientists, WuXi PharmaTech
This article was originally published in PharmAsia News
Executive Summary
BEIJING - Pfizer is set to ramp up its research and development center in Shanghai and to integrate more Chinese scientists into its worldwide virtual R&D network, including a new research deal with Wuxi PharmaTech, according to senior Pfizer executives in Shanghai and Hong Kong
You may also be interested in...
Pfizer R&D In China: Building A Virtual R&D Network
While many multinational companies have taken a brick-and-mortar approach to R&D in emerging markets, Pfizer is betting that a virtual research network will give it the flexibility and access to talent it needs to succeed in China. Pfizer's president of global R&D, Martin Mackay, and Stephen Yang, who heads Pfizer's Asia R&D efforts, outline that strategy in a two-part interview. Two of the most important figures in Pfizer's worldwide research endeavors, Mackay and Yang were interviewed by Elsevier writers Ellen Licking and Wendy Diller. This is part one of the interview; part two will appear in an upcoming issue of PharmAsia News.
Pfizer R&D In China: Building A Virtual R&D Network
While many multinational companies have taken a brick-and-mortar approach to R&D in emerging markets, Pfizer is betting that a virtual research network will give it the flexibility and access to talent it needs to succeed in China. Pfizer's president of global R&D, Martin Mackay, and Stephen Yang, who heads Pfizer's Asia R&D efforts, outline that strategy in a two-part interview. Two of the most important figures in Pfizer's worldwide research endeavors, Mackay and Yang were interviewed by Elsevier writers Ellen Licking and Wendy Diller. This is part one of the interview; part two will appear in an upcoming issue of PharmAsia News.
AstraZeneca Outsources Drug Discovery Research To BioDuro For Respiratory And Inflammation Indications
SHANGHAI - AstraZeneca is expanding its research collaboration with contract research organization BioDuro to cooperate on drug discovery research in respiratory and inflammation diseases in China, the two companies announced March 23